Total Body Perfusion in Patients With Chest Pain

NCT ID: NCT05825859

Last Updated: 2023-04-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-11

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Purpose of this study is to better understand changes in obstructive coronary artery disease in different organs other than the heart such as the brain and the kidneys using a new generation total body PET scanner.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with chest pain and suspected CAD will be studied using total body PET imaging with O15-water perfusion imaging

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented history of chest pain with CT imaging showing a potential for obstructive coronary artery disease
* Ability to sustain adenosine injection 0.14 mg/kg/min

Exclusion Criteria

* Second or third degree AV-block without pacemaker
* Sick sinus syndrome
* Consumption of coffee or aminophylline within 12 hours of administration
* Recent use of dipyridmole or dipyridamole-containing medications
* Known hypersensitivity to adenosine
* Unstable acute MI or acute coronary artery syndrome, and prior cardiac transplantation
* Active wheezing and bronchospasm
* Sinus bradycardia with HR\<40 bmp
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Turku University Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Juhani Knuuti

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Juhani Knuuti, MD

Role: PRINCIPAL_INVESTIGATOR

Turku University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Turku University Hospital

Turku, , Finland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Finland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Juhani Knuuti, MD

Role: CONTACT

+358500592998

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Juhani Knuuti, MD

Role: primary

+358500592998

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KOVERI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MRI Evaluation of Chest Pain
NCT00001961 COMPLETED PHASE2
Cancer Survivor Cardiomyopathy Detection
NCT05201014 ACTIVE_NOT_RECRUITING